Ads
-
Related paper
- DAMAGE OF RENAL FUNCTION AND DYNAMICS OF DYSLIPIDEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH INSUFFICIENT GLYCEMIC COMPENSATION UNDER CONDITION OF CORRECTION OF HYPERTENSION WITH ANGIOTENSIN II RECEPTOR ANTAGONISTS
- Dynamics of endothelial dysfunction, nephropathic and dyslipidemic disorders in patients with insufficient glycemic compensation of type 2 diabetes mellitus during 1 year of application of angiotensin II receptor antagonists for hypertension correction
- Relationship of endothelial dysfunction with degree of renal function damage and lipidemic profile in patients with type 2 diabetes mellitus and hypertension
- Endothelial function in patients with diabetes mellitus type 2 with arterial hypertension in good compensation of hyperglycemia
- Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus
- Pathomechanism of Renal Damage in Type 2 Diabetes Mellitus Patients
- GLUCOSE METABOLISM CHARACTERISTICS AND THE I/D GENE POLYMORPHISM OF THE ANGIOTENSIN-CONVERTING ENZYME IN THE PATIENTS WITH ARTERIAL HYPERTENSION ACCOMPANYING WITH A TYPE II DIABETES MELLITUS
- Role of Glycated Haemoglobin (HbA1c) as a Dual Marker to Predict Glycemic Status and Dyslipidemia in Type II Diabetes Mellitus
- A Cross-Sectional Study of Pulmonary Function Tests in Type 2 Diabetes Mellitus and Correlation with Glycemic Index and Duration of Diabetes
- The impact of three combinations vildagliptin/metformin, vildagliptin/pioglitazone, and metformin/pioglitazone on glycemic control and atherogenic dyslipidemia in patients with Type 2 diabetes mellitus